Skip to main content

Meropenem / vaborbactam Side Effects

Medically reviewed by Drugs.com. Last updated on Mar 22, 2023.

Applies to meropenem / vaborbactam: intravenous powder for solution.

Serious side effects

Along with its needed effects, meropenem / vaborbactam may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking meropenem / vaborbactam:

Less common

Rare

Other side effects

Some side effects of meropenem / vaborbactam may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common

For Healthcare Professionals

Applies to meropenem / vaborbactam: intravenous powder for injection.

General

The most common side effects were headache, phlebitis/infusion site reactions, infusion site phlebitis, diarrhea, and nausea. This drug was discontinued due to a side effect in 2.9% (8/272) of patients (compared to 5.1% [14/273] of patients using piperacillin-tazobactam); therapy was discontinued most commonly due to hypersensitivity and infusion-related reactions. Death occurred in 0.7% of patients using this drug and in 0.7% of patients using piperacillin-tazobactam.[Ref]

Nervous system

Common (1% to 10%): Headache

Uncommon (0.1% to 1%): Dizziness, tremor, paresthesia, lethargy

Meropenem:

-Rare (0.01% to 0.1%): Convulsions[Ref]

Local

Common (1% to 10%): Phlebitis/infusion site reactions (included infusion/injection site phlebitis, infusion site thrombosis, infusion site erythema), infusion site phlebitis

Uncommon (0.1% to 1%): Infusion site erythema, injection site phlebitis, infusion site thrombosis, infusion related reaction[Ref]

Gastrointestinal

Common (1% to 10%): Diarrhea, nausea, vomiting

Uncommon (0.1% to 1%): Abdominal distension, Clostridioides difficile colitis, oral candidiasis

Frequency not reported: C difficile-associated diarrhea

Meropenem:

-Uncommon (0.1% to 1%): Abdominal pain[Ref]

Hypersensitivity

Common (1% to 10%): Hypersensitivity (included hypersensitivity, drug hypersensitivity, anaphylactic reaction, rash, urticaria, bronchospasm)

Uncommon (0.1% to 1%): Anaphylactic reaction[Ref]

Hepatic

Common (1% to 10%): Increased ALT, increased AST

Meropenem:

-Uncommon (0.1% to 1%): Increased blood bilirubin

-Frequency not reported: Jaundice[Ref]

Other

Common (1% to 10%): Pyrexia

Uncommon (0.1% to 1%): Chest discomfort

Meropenem:

-Common (1% to 10%): Increased blood alkaline phosphatase, increased blood LDH

-Uncommon (0.1% to 1%): Pain[Ref]

Metabolic

Common (1% to 10%): Hypokalemia, hypoglycemia

Uncommon (0.1% to 1%): Decreased appetite, hyperkalemia, hyperglycemia[Ref]

Cardiovascular

Common (1% to 10%): Hypotension

Uncommon (0.1% to 1%): Vascular pain

Frequency not reported: Deep vein thrombosis[Ref]

Dermatologic

Uncommon (0.1% to 1%): Rash, urticaria

Meropenem:

-Uncommon (0.1% to 1%): Pruritus

-Postmarketing reports: Toxic epidermal necrolysis, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome, erythema multiforme, angioedema[Ref]

Hematologic

Uncommon (0.1% to 1%): Leukopenia

Meropenem:

-Common (1% to 10%): Thrombocytosis/thrombocythemia

-Uncommon (0.1% to 1%): Neutropenia, eosinophilia, thrombocytopenia

-Frequency not reported: Decreased blood thromboplastin, decreased prothrombin time

-Postmarketing reports: Agranulocytosis, hemolytic anemia, positive direct and indirect Coombs test[Ref]

Musculoskeletal

Uncommon (0.1% to 1%): Increased blood creatine phosphokinase[Ref]

Psychiatric

Uncommon (0.1% to 1%): Hallucination, insomnia[Ref]

Renal

Uncommon (0.1% to 1%): Renal impairment

Frequency not reported: Azotemia

Meropenem:

-Uncommon (0.1% to 1%): Increased blood creatinine, increased blood urea[Ref]

Respiratory

Uncommon (0.1% to 1%): Bronchospasm

Frequency not reported: Pharyngitis[Ref]

Genitourinary

Uncommon (0.1% to 1%): Vulvovaginal candidiasis, incontinence[Ref]

References

1. Cerner Multum, Inc. UK Summary of Product Characteristics.

2. Product Information. Vabomere (meropenem-vaborbactam). The Medicines Company. 2017.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.